Prudent Man Advisors LLC Decreases Stake in Elevance Health, Inc. (NYSE:ELV)

Prudent Man Advisors LLC reduced its stake in Elevance Health, Inc. (NYSE:ELV) by 17.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,229 shares of the company’s stock after selling 253 shares during the period. Prudent Man Advisors LLC’s holdings in Elevance Health were worth $453,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. Raelipskie Partnership purchased a new position in shares of Elevance Health during the third quarter valued at approximately $26,000. Crews Bank & Trust purchased a new position in shares of Elevance Health during the fourth quarter valued at approximately $34,000. Dunhill Financial LLC increased its stake in shares of Elevance Health by 57.8% during the third quarter. Dunhill Financial LLC now owns 71 shares of the company’s stock valued at $37,000 after buying an additional 26 shares during the period. Peterson Financial Group Inc. purchased a new position in shares of Elevance Health during the third quarter valued at approximately $44,000. Finally, Financial Perspectives Inc purchased a new position in shares of Elevance Health during the fourth quarter valued at approximately $50,000. 89.24% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ELV has been the topic of several research analyst reports. Mizuho reduced their target price on Elevance Health from $585.00 to $505.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 5th. Truist Financial reduced their price target on Elevance Health from $520.00 to $480.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Barclays upped their price target on Elevance Health from $501.00 to $512.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Argus reaffirmed a “hold” rating and issued a $405.40 price target on shares of Elevance Health in a research note on Wednesday, January 29th. Finally, Wells Fargo & Company reduced their price target on Elevance Health from $483.00 to $478.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 28th. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $517.03.

Elevance Health Trading Up 1.1 %

Elevance Health stock opened at $397.09 on Friday. The company has a current ratio of 1.45, a quick ratio of 1.50 and a debt-to-equity ratio of 0.71. The business’s fifty day simple moving average is $387.78 and its two-hundred day simple moving average is $439.07. Elevance Health, Inc. has a 12 month low of $362.21 and a 12 month high of $567.26. The company has a market capitalization of $90.28 billion, a price-to-earnings ratio of 15.51, a price-to-earnings-growth ratio of 1.18 and a beta of 0.83.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Thursday, January 23rd. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.80 by $0.04. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%. As a group, equities analysts predict that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 25th. Stockholders of record on Monday, March 10th will be issued a dividend of $1.71 per share. This is an increase from Elevance Health’s previous quarterly dividend of $1.63. This represents a $6.84 dividend on an annualized basis and a dividend yield of 1.72%. The ex-dividend date is Monday, March 10th. Elevance Health’s dividend payout ratio is presently 26.71%.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.